CareDx demonstrates a mature and differentiated business model with strong recurring revenue growth driven by integrated diagnostics and digital solutions in the transplant market. Although the overall transplant procedure volume is flat, CareDx’s ability to increase test volumes and revenue per te…
CareDx (CDNA) Q3 2025: Revenue Surges 21% with RCM Driving Durable ASP Gains
CareDx delivered robust third quarter growth led by record testing volumes and revenue cycle management (RCM) improvements that enhanced revenue per test (ASP) durability. The company’s solution-selling strategy and operational investments underpin raised full-year guidance, positioning CareDx for sustained expansion amid a stable transplant market. Continued innovation and integration efforts signal further growth catalysts ahead.
Summary
- End-to-End Transplant Leadership: CareDx’s comprehensive transplant solutions deepen clinical engagement and patient care integration.
- Operational Efficiency Gains: RCM and Epic Aura integrations materially improve cash collections and testing workflow efficiency.
- Strategic Innovation Pipeline: Launches like HistoMap Kidney and AlloSeq Tx11 reinforce product differentiation and future growth prospects.
Business Overview
CareDx is a precision medicine company specializing in genomics-based diagnostics and digital healthcare solutions for transplant patients. Its revenue is generated primarily through three segments: testing services, patient and digital solutions, and lab products, serving transplant centers with end-to-end offerings that span pre- and post-transplant patient management.
Performance Analysis
In Q3 2025, CareDx reported total revenue of $100.1 million, a 21% increase year-over-year, driven by strong volume growth of 13% to approximately 50,300 tests in its core testing services segment, which accounted for $72.2 million of revenue. This volume expansion was supported by a 5% increase in revenue per test to $1,436, reflecting improved cash collections and reimbursement dynamics. Patient and digital solutions revenue surged 30% to $15.4 million, while lab products revenue grew 22% to $12.5 million.
Gross margins expanded 190 basis points to 70.9%, benefiting from top-line growth and disciplined input cost management. Operating leverage was evident as non-GAAP operating expenses declined as a percentage of revenue to 58%, leading to adjusted EBITDA of $15.3 million, more than doubling the prior year quarter’s $6.9 million. Cash collections reached a record $119 million, with accounts receivable days sales outstanding (DSO) improving from 71 to 44 days, underscoring the effectiveness of RCM initiatives.
- Revenue Mix Strength: Testing services remain the largest revenue driver, with patient and digital solutions and lab products showing accelerated growth.
- Margin Expansion: Gross margin improvement and operating expense control highlight scalable business model execution.
- Cash Flow Optimization: RCM improvements translate into higher cash collections and reduced receivables, enhancing financial flexibility.
Overall, CareDx’s financial performance reflects a maturing business with strong operational momentum and improving profitability metrics.
Executive Commentary
"Our strategy of solution selling is working. We are uniquely positioned as the only company serving transplant patients from end to end, delivering innovative diagnostics, digital tools, and patient support that span the entire transplant journey."
John W. Hanna, President and CEO
"The momentum of the business at CareDx is robust. We are delivering a unique combination of top-line expansion, margin improvement, and op-ex management. Results in Q3 are a testament to the execution and our ability to scale efficiently while controlling costs."
Nathan Smith, Chief Financial Officer
Strategic Positioning
1. Solution Selling and Customer-Centric Innovation
CareDx emphasizes a patient and clinician-centered approach, integrating testing services with digital and pharmacy solutions to deepen clinical partnerships. This strategy fosters customer loyalty and drives cross-segment revenue growth, as seen in 30% growth in patient and digital solutions.
2. Revenue Cycle Management as a Growth Lever
The company’s investments in RCM, including AI-driven automation, have accelerated cash collections and reduced claims rejections, directly supporting a sustainable increase in revenue per test. Record collections exceeding booked revenue by 24% in the quarter indicate durable ASP gains and improved revenue predictability.
3. Epic Aura Integration Enhancing Operational Efficiency
With eight live Epic Aura integrations and plans for 40 centers in 2026, CareDx is streamlining test ordering and results delivery. Early pilots show 20% reduction in order turnaround time and 60% fewer specimen holds, enhancing clinician workflows and expected to drive volume uplifts.
4. Robust Innovation Pipeline with HistoMap Kidney and AlloSeq Tx11
New product launches, such as the tissue-based molecular profiling HistoMap Kidney and next-gen HLA typing AlloSeq Tx11, demonstrate CareDx’s commitment to clinical differentiation. These innovations address unmet needs in transplant care and regulatory compliance, positioning the company for sustained lab products growth.
5. Evidence Generation and Policy Advocacy
CareDx’s leadership in publishing landmark studies like the SHORE registry and submitting comprehensive policy comments supports reimbursement and clinical adoption. The company is actively shaping molecular testing coverage policies, which are critical for future revenue stability and growth.
Key Considerations
CareDx’s Q3 results reflect the execution of a multi-pronged strategy combining innovation, operational excellence, and market expansion in a complex transplant ecosystem.
- Market Penetration Opportunity: Despite flat overall transplant volumes, CareDx expects to outpace market growth through increased surveillance testing and protocol adoption.
- RCM Momentum: Continued improvements in revenue cycle processes are key to sustaining ASP gains and cash flow quality.
- Regulatory Uncertainty: Finalization of LCD policy in early 2026 remains a material event, with potential reimbursement impacts but no expected near-term utilization changes.
- Innovation Adoption: New product launches are expected to contribute incremental revenue but require ongoing evidence generation and reimbursement strategies.
- Share Repurchase Activity: The company repurchased approximately 9% of shares year-to-date, reflecting confidence in capital allocation and shareholder value creation.
Risks
Risks include potential reimbursement changes from the pending LCD policy, variability in transplant procedure volumes influenced by external factors, and execution risks related to scaling Epic Aura integrations and new product commercialization. Competitive dynamics appear limited but warrant monitoring as market penetration deepens.
Forward Outlook
For Q4 2025, CareDx guided revenue between $101 million and $105 million, with testing volumes expected between 52,000 and 54,000 tests. Revenue per test is forecasted at $1,400 to $1,420, inclusive of $4 million to $6 million in cash collections exceeding receivables. Patient and digital solutions revenue is projected at $15 million to $16 million, with lab products revenue of $12 million to $12.5 million. Adjusted EBITDA guidance ranges from $10 million to $14 million. Full-year 2025 revenue guidance was raised to $372 million to $376 million, and adjusted EBITDA guidance increased to $35 million to $39 million, reflecting strong operational execution.
Takeaways
CareDx’s Q3 performance signals a maturing business capitalizing on operational improvements and strategic innovation to drive durable growth.
- Operational Leverage Confirmed: Revenue growth coupled with margin expansion and RCM enhancements underpin improved profitability and cash flow quality.
- Innovation Fuels Differentiation: Product launches and evidence generation strengthen clinical adoption and reimbursement positioning, supporting long-term growth.
- Regulatory Clarity Pending: LCD policy finalization in early 2026 is a key event to watch for potential impact on reimbursement and utilization trends.
Conclusion
CareDx’s Q3 2025 results demonstrate effective execution of a patient-centric, solutions-driven strategy that is delivering strong revenue growth, margin expansion, and operational improvements. The company’s raised guidance and robust innovation pipeline position it well for continued leadership in transplant diagnostics and care.
Industry Read-Through
CareDx’s success in integrating diagnostics with digital and pharmacy solutions illustrates a broader industry trend towards comprehensive, data-driven transplant care. The positive impact of RCM automation and Epic integrations signals operational best practices other labs may adopt to improve cash flow and customer experience. Additionally, ongoing policy developments around molecular testing reimbursement will be critical for the transplant diagnostics sector, with CareDx’s advocacy efforts serving as a bellwether for coverage evolution.